Johnson & Johnson pauses COVID-19 vaccine clinical trials
Drug maker Johnson & Johnson Oct. 12 announced the pause of its large-scale, pivotal, multi-country phase 3 trial for its JNJ-78436735 COVID-19 vaccine candidate. The pause is the result of an unexplained illness in a study volunteer participant. Johnson & Johnson announced the start of its phase 3 trial for the Janssen Pharmaceutical Companies-developed vaccine on Sept. 23.
Related News Articles
Headline
The Food and Drug Administration July 10 approved Moderna’s Spikevax COVID-19 vaccine for children under 12 with at least one underlying condition that…
Headline
The Occupational Safety and Health Administration June 30 released a proposed rule to remove what remains of its emergency temporary standard for occupational…
Headline
Department of Health and Human Services Secretary Robert F. Kennedy Jr. May 27 announced in a post on X that the Centers for Disease Control and Prevention…
Headline
Leaders of the Food and Drug Administration May 20 announced new guidelines for administering the COVID-19 vaccine in a paper published by the New England…
Headline
A study published April 8 by the Public Library of Science’s Journal of Global Public Health found that driving while infected with COVID-19 raises the risk of…
Headline
The Senate Finance Committee Feb. 4 voted 14-13 to advance Robert F. Kennedy Jr.’s nomination for secretary of the Department of Health and Human Services. A…